Form 4: Heron Therapeutics CFO Receives Equity Awards

Heron Therapeutics' EVP and CFO, Ira Duarte, received significant equity grants comprising Restricted Stock Units and Performance Stock Units, vesting over four years.

Summary

• Ira Duarte, Executive Vice President and Chief Financial Officer of Heron Therapeutics, Inc. (HRTX), was granted equity awards on January 30, 2026.
• The awards include 216,562 Restricted Stock Units (RSUs) and 216,561 Performance Stock Units (PSUs).
• The RSUs will vest in 16 equal quarterly installments, beginning one quarter after the January 30, 2026 grant date.
• The PSUs will also vest in 16 equal quarterly installments, starting one quarter after the grant date, but are subject to the satisfaction of a milestone-based vesting condition.
• The PSU vesting condition is based on a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the Issuer's Form 10-K.
• Both RSUs and PSUs convert into common stock on a one-for-one basis.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard executive compensation event that aligns the CFO's interests with long-term shareholder value through a mix of time-based and performance-based equity awards.

Positives

• The equity grants align the EVP and CFO's compensation directly with the long-term performance and shareholder interests of Heron Therapeutics.
• The inclusion of Performance Stock Units (PSUs) ties a significant portion of executive compensation to the achievement of specific net product sales revenue targets, incentivizing growth.
• The four-year vesting schedule for both RSUs and PSUs promotes executive retention and encourages sustained focus on company performance.

Negatives

• The specific net product sales revenue target for the PSUs is not disclosed, making it difficult to assess the challenge or likelihood of achieving the performance condition.
• The future conversion of RSUs and PSUs into common stock could lead to dilution for existing shareholders.

Future Outlook

The vesting of Performance Stock Units is contingent upon achieving a net product sales revenue target for the fiscal year ending December 31, 2026, indicating a strategic focus on future sales growth and financial performance.

Industry Context

StockSavvy.ai notes that equity grants, particularly those with performance conditions, are a common practice in the biotechnology and pharmaceutical industries to align executive incentives with long-term company performance and shareholder value creation. This is a standard component of executive compensation packages.

Comparison to Industry Standards

• Equity grants of this magnitude for a CFO in a biotechnology company like Heron Therapeutics are generally consistent with industry practices for executive compensation, aiming to retain key talent and incentivize performance.
• The combination of time-based RSUs and performance-based PSUs is a common compensation structure, similar to packages observed at peers such as Acadia Pharmaceuticals (ACAD) or Neurocrine Biosciences (NBIX), which frequently utilize a mix of equity types to balance retention and performance incentives.

Stakeholder Impact

• Shareholders: Potential for future dilution upon conversion of RSUs and PSUs; increased alignment of executive incentives with company performance.
• Employees: May signal confidence in the company's future and provide a benchmark for executive compensation practices.

Next Steps

• Vesting of Restricted Stock Units (RSUs) in 16 equal quarterly installments beginning one quarter after January 30, 2026.
• Vesting of Performance Stock Units (PSUs) in 16 equal quarterly installments beginning one quarter after January 30, 2026, contingent on achieving a net product sales revenue target for the fiscal year ending December 31, 2026.
• Reporting of the net product sales revenue target achievement in the Issuer's Form 10-K for the fiscal year ending December 31, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, aligning their incentives with the company's long-term performance. It does not provide new information that would fundamentally alter the investment thesis for Heron Therapeutics, hence a 'hold' recommendation is maintained.

Keywords

Heron Therapeutics, HRTX, Ira Duarte, EVP, Chief Financial Officer, Restricted Stock Units, RSUs, Performance Stock Units, PSUs, Equity Grant, Executive Compensation, Insider Transaction, Form 4